White Pine Capital LLC Acquires 542 Shares of Kenvue Inc. (NYSE:KVUE)

White Pine Capital LLC boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% in the fourth quarter, HoldingsChannel reports. The firm owned 54,572 shares of the company’s stock after purchasing an additional 542 shares during the quarter. White Pine Capital LLC’s holdings in Kenvue were worth $1,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of KVUE. State Street Corp boosted its holdings in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after buying an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the period. Holocene Advisors LP lifted its position in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after acquiring an additional 5,975,392 shares during the last quarter. M&G PLC boosted its holdings in shares of Kenvue by 538.0% during the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after acquiring an additional 3,660,730 shares during the period. Finally, FMR LLC grew its position in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.47 on Friday. The firm has a 50 day moving average of $21.37 and a 200-day moving average of $22.03. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $41.15 billion, a PE ratio of 40.50, a PEG ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts predict that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on KVUE shares. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Canaccord Genuity Group lowered their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.